MOUNTAIN VIEW, Calif. — November 4, 2025 — Leads & Copy —
RenovoRx, Inc. (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate in the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025.
Bagai will provide updates on RenovoRx’s commercialization progress and highlight developments from the Phase III TIGeR-PaC clinical trial, which is evaluating the company’s drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath known as IAG) in locally advanced pancreatic cancer (LAPC). Additionally, Bagai will discuss the recently launched post-marketing observational registry study designed to evaluate the long-term safety signals and survival outcomes for patients diagnosed with solid tumors receiving cancer treatment delivered via RenovoCath.
The Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum will be held at the Westin NY Grand Central in New York, NY.
To schedule a one-on-one investor meeting with Mr. Bagai, please contact your Canaccord Genuity representative or KCSA Strategic Communications at RenovoRx@KCSA.com.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRx@KCSA.com
Source: RenovoRx, Inc.
